The efficacy of combination immunotherapy in experimental Pseudomonas sepsis.
Immunotherapy has been shown to be an effective adjuvant in the management of septic shock. A neutropenic rat model of septic shock induced by infection with Pseudomonas aeruginosa 12.4.4 (Fisher immunotype 6) was used to determine the relative efficacy of single, double, and triple combination immunotherapy. A Pseudomonas O serotype-specific, opsonophagocytic monoclonal antibody (MAb), polyclonal J5 antiserum, and a MAb directed against tumor necrosis factor-alpha (TNF) were studied as single therapy and in combination. The combination of all three immunotherapeutic agents resulted in a 77% survival rate (33/43 animals). This level of protection was superior to that achieved with any combination of two antibody treatments (50%-60% survival; P = .029) or single antibody therapy (25%-43% survival; P < .001) or compared with a control group (0/25 survivors; P < .0001). Immunotherapy directed against multiple steps of the septic process is more active than single or double antibody regimens and may offer an improved approach to the adjunctive treatment of septic shock.
Cross
A S
AS
Division of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC 20307-5100.
Opal
S M
SM
Palardy
J E
JE
Bodmer
M W
MW
Sadoff
J C
JC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006224:Cricetinae; D004195:Disease Models, Animal; D005260:Female; D007167:Immunotherapy; D009503:Neutropenia / Q000628:therapy; D011552:Pseudomonas Infections / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012772:Shock, Septic / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000276:immunology*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha